Showing results (81-90 of 106) with videos related to

Sort By:
Pageof 11
Journal of Clinical and Translational Hepatology|April 10, 2025
Prevalence of Hepatitis D Virus Antibody Positivity in Chinese Patients with Chronic Hepatitis B Virus InfectionXieer Liang, Qiaoqiao Chen, Hong Tang, et al.
Diagnostics (Basel, Switzerland)|January 28, 2026
Use of Artificial Intelligence-Assisted Histopathology for Evaluation of Sex-Specific Progression and Regression of Hepatocellular Carcinoma Related to Metabolic Dysfunction-Associated Fatty Liver DiseaseKe Yin, Yuyun Song, Ran Fei, et al.
Expert Opinion on Biological Therapy|July 8, 2021
Pharmacokinetic bioequivalence, safety, and immunogenicity of GB222, a bevacizumab biosimilar candidate, and bevacizumab in Chinese healthy males: a randomized clinical trialWenliang Dong, Min Chen, Suping Niu, et al.
Zhonghua Nei Ke Za Zhi|December 18, 2015
[The efficacy and prognostic predictors of different treatment courses with pegylated interferon α-2a and ribavirin combination in recurrent chronic hepatitis C patients]Huiying Rao, Ruifeng Yang, Jia Shang, et al.
Hepatology (Baltimore, Md.)|May 25, 2011
MicroRNAs-372/373 promote the expression of hepatitis B virus through the targeting of nuclear factor I/BHongyan Guo, Haiying Liu, Keith Mitchelson, et al.
Zhonghua Gan Zang Bing Za Zhi = Zhonghua Ganzangbing Zazhi = Chinese Journal of Hepatology|August 4, 2015
[High sustained virological response to optimized therapy for refractory chronic hepatitis C treatment-na(i)ve patients: a multicenter randomized study]Xinyue Chen, Jia Shang, Ruifeng Yang, et al.
JBMR Plus|October 5, 2018
Is Retinal Microvascular Abnormalities an Independent Risk Factor of Vertebral Fractures? A Prospective Study From a Chinese PopulationJunping Wen, Kaka Tang, Fengye Zhu, et al.
BMJ Open|June 20, 2023
Stages of psychological change among patients with non-alcoholic fatty liver disease in China: a national cross-sectional studyRui Huang, Jian-Gao Fan, Jun-Ping Shi, et al.
Communications Medicine|December 9, 2025
Transparent and dynamic network-based risk assessment for development of hepatic encephalopathyZixing Wang, Suzhen Jiang, Feng Liu, et al.
Frontiers in Pharmacology|July 5, 2022
A Randomized Controlled Dose-Escalation Study of LY06006, a Recombinant Humanized Monoclonal Antibody to RANKL, in Chinese Healthy AdultsSuping Niu, Min Chen, Diqin Yan, et al.
Pageof 11